Copyright
©The Author(s) 2021.
World J Diabetes. Jan 15, 2021; 12(1): 84-97
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84
Published online Jan 15, 2021. doi: 10.4239/wjd.v12.i1.84
Table 1 Summary of included studies
Ref. | Study duration | Population | Assessment of NAFLD | Intervention | No. of participants |
Alam et al[18], 2018 | 52 wk | NAFLD | Biopsy | Sitagliptin 100 mg QD + lifestyle modification | 20 |
Lifestyle modification | 20 | ||||
Cui et al[19], 2017 | 24 wk | NAFLD with prediabetes or early diabetes | MRI | Sitagliptin 100 mg QD | 25 |
PBO | 25 | ||||
Hussain et al[20], 2016 | 12 wk | NAFLD + dyslipidemia | Ultrasound | Vildagliptin 50 mg Bid | 29 |
PBO | 29 | ||||
Macauley et al[21], 2015 | 6 mo | T2DM with hepatic steatosis | Imaging (CT or ultrasound) | Vildagliptin 50 mg Bid | 22 |
PBO | 22 | ||||
Joy et al[22], 2017 | 24 wk | NASH | Biopsy | Sitagliptin 100 mg QD | 6 |
PBO | 6 | ||||
Li et al[23], 2019 | 24 wk | T2DM with NAFLD | Imaging or biopsy | Saxagliptin 5 mg QD | 31 |
Glimepiride 2 mg QD | 33 | ||||
Glimepiride 2 mg QD + polyenephosphatidylcholine 456 mg TID | 31 | ||||
Yan et al[24], 2019 | 26 wk | T2DM with NAFLD | MRI | Liraglutide 1.8 mg + metformin | 24 |
Sitagliptin + metformin | 27 | ||||
Glargine 0.2 IU/Kg/d + metformin | 24 | ||||
Armstrong et al[25], 2016 | 48 wk | T2DM with NASH | Biopsy | Liraglutide 1.8 mg QD | 26 |
PBO | 26 | ||||
Cusi et al[26], 2018 | 6 mo | T2DM with NAFLD/NASH | Laboratory liver tests | Duraglutide 1.5 mg QW | 971 |
PBO | 528 | ||||
Fan et al[27], 2013 | 12 wk | T2DM with NAFLD | Ultrasound | Exenatide | 49 |
Metformin | 68 | ||||
Feng et al[28], 2017 | 24 wk | T2DM with NAFLD | Ultrasound | Metformin 1000 mg Bid | 29 |
Gliclazide 120 mg/d | 29 | ||||
Liraglutide 1.8 mg QD | 29 | ||||
Khoo et al[29], 2017 | 26 wk | NAFLD | MRI | Liraglutide 3.0 mg QD | 12 |
Diet and exercise | 12 | ||||
Shao et al[30], 2014 | 12 wk | T2DM with NAFLD | Ultrasound | Exenatide 10 μg bid + glargine | 30 |
Intensive insulin therapy | 30 | ||||
Tian et al[31], 2018 | 12 wk | T2DM with NAFLD | Ultrasound | Liraglutide 0.6-1.2 mg QD | 52 |
Metformin 1000-1500 mg/d | 75 | ||||
Eriksson et al[32], 2018 | 12 wk | T2DM with NAFLD | MRI | Dapagliflozin 10 mg QD | 21 |
PBO | 21 | ||||
Dapagliflozin 10 mg QD + OM-3CA | 22 | ||||
OM-3CA 4 g | 20 | ||||
Ito et al[33], 2017 | 24 wk | T2DM with NAFLD | Clinical laboratorytests or imaging | Ipragliflozin 50 mg QD | 32 |
Pioglitazone 15–30 mg QD | 34 | ||||
Kuchay et al[34], 2018 | 20 wk | T2DM with NAFLD | MRI | Empagliflozin 10 mg QD | 22 |
Control | 20 | ||||
Shibuya et al[35], 2018 | 6 mo | T2DM with NAFLD | Imaging (CT or ultrasound) | Luseogliflozin 2.5 mg QD | 16 |
Metformin 1500 mg QD | 16 | ||||
Shimizu et al[36], 2018 | 24 wk | T2DM with NAFLD | Transient elastography | Dapagliflozin 5 mg QD | 33 |
Control | 24 |
Table 2 Comparison of body weight and body mass index changes from baseline in different treatment groups
Studies | Participants | WMD | 95%CI | P value | ||
Body weight change | ||||||
DPP-4 inhibitors | 4 | 140/138 | -1.20 | -1.44 | -0.95 | < 0.0001 |
GLP-1 RAs | 8 | 1222/821 | -3.61 | -5.74 | -1.48 | 0.0009 |
SGLT2 inhibitors | 5 | 146/135 | -2.53 | -3.35 | -1.71 | < 0.0001 |
BMI change | ||||||
DPP-4 inhibitors | 5 | 144/146 | -0.59 | -1.80 | 0.61 | 0.33 |
GLP-1 RAs | 7 | 251/293 | -1.46 | -2.23 | -0.69 | 0.0002 |
SGLT2 inhibitors | 4 | 114/101 | -1.72 | -2.68 | -0.75 | 0.0005 |
Table 3 Comparison of hemoglobin A1c change from baseline in different treatment groups
Studies | Participants | WMD | 95%CI | P value | ||
HbA1c change | ||||||
DPP-4 inhibitors | 6 | 166/166 | -0.42 | -0.58 | -0.25 | < 0.0001 |
GLP-1 RAs | 7 | 1210/809 | -0.29 | -0.85 | 0.26 | 0.30 |
SGLT2 inhibitors | 5 | 146/135 | -0.36 | -0.80 | 0.08 | 0.11 |
HbA1c change (placebo-controlled studies only) | ||||||
DPP-4 inhibitors | 5 | 102/102 | -0.38 | -0.71 | -0.05 | 0.02 |
GLP-1 RAs | 3 | 1009/566 | -0.88 | -1.56 | -0.19 | 0.01 |
SGLT2 inhibitors | 1 | 21/21 | -0.50 | -0.84 | -0.16 | 0.004 |
Table 4 Comparison of magnetic resonance imaging proton density fat fraction and visceral fat area change from baseline in different treatment groups
Studies | Participants | WMD | 95%CI | P value | ||
MRI-PDFF change | ||||||
DPP-4 inhibitors | 2 | 52/49 | -2.31 | -4.92 | 0.29 | 0.08 |
GLP-1 RAs | 1 | 24/24 | -3.20 | -5.98 | -0.42 | 0.02 |
SGLT2 inhibitors | 2 | 65/61 | -1.18 | -2.38 | 0.03 | 0.06 |
VFA change | ||||||
DPP-4 inhibitors | 1 | 27/24 | -23.10 | -38.84 | -7.36 | 0.004 |
GLP-1 RAs | 1 | 24/24 | -30.40 | -46.86 | -13.94 | 0.0003 |
SGLT2 inhibitors | 2 | 48/50 | -23.48 | -25.85 | -21.12 | < 0.0001 |
Table 5 Meta-regression analyses of association between weight change difference and difference of alanine aminotransferase, aspartate aminotransferase, magnetic resonance imaging proton density fat fraction, and visceral fat area between antidiabetes drugs and controls (ß coefficient value, P value, and 95%CI are shown)
ß | P value | 95%CI | |
ALT | 0.064 | 0.267 | -0.053-0.181 |
AST | 0.020 | 0.735 | -0.104-0.144 |
MRI-PDFF | 0.308 | 0.701 | -2.678-3.294 |
VFA | 1.776 | 0.343 | -11.723-15.275 |
- Citation: Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97
- URL: https://www.wjgnet.com/1948-9358/full/v12/i1/84.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i1.84